Dendreon Corporation – Product Pipeline Review – H2 2011 by GlobalMarketsDirect

VIEWS: 3 PAGES: 85

More Info
									Dendreon Corporation – Product Pipeline Review – H2
                       2011
                                                                                          Reference Code: GMDHC01747CDB

                                                                                                 Publication Date: NOV 2011




Dendreon Corporation – Product Pipeline Review – H2 2011                                    GMDHC01747CDB / Published NOV 2011

© Global Markets Direct. This report is a licensed product and is not to be photocopied                                 Page(1)
Dendreon Corporation – Product Pipeline Review




Ta b le o f Co n te n ts
Table of Contents ..................................................................................................................................................................................................... 2
      List of Tables...................................................................................................................................................................................................... 5
      List of Figures .................................................................................................................................................................................................... 6
Dendreon Corporation Snapshot .............................................................................................................................................................................. 7
      Dendreon Corporation Overview ........................................................................................................................................................................ 7
      Key Information .................................................................................................................................................................................................. 7
      Key Facts ........................................................................................................................................................................................................... 7
Dendreon Corporation – Research and Development Overview ............................................................................................................................... 8
      Key Therapeutic Areas ....................................................................................................................................................................................... 8
Dendreon Corporation – Pipeline Review ................................................................................................................................................................11
      Pipeline Products by Stage of Development ......................................................................................................................................................11
      Dendreon Corporation – Pipeline Products Glance ...........................................................................................................................................12
      Dendreon Corporation Clinical Stage Pipeline Products ....................................................................................................................................12
            Phase II Products/Combination Treatment Modalities .................................................................................................................................12
            Phase I Products/Combination Treatment Modalities ..................................................................................................................................13
      Dendreon Corporation–Early Stage Pipeline Products ......................................................................................................................................14
            Pre-Clinical Products/Combination Treatment Modalities ............................................................................................................................14
            Discovery Products/Combination Treatment Modalities ..............................................................................................................................15
Dendreon Corporation – Drug Profiles .....................................................................................................................................................................16
      Anti-Serine Protease Monoclonal Antibodies .....................................................................................................................................................16
            Product Description ....................................................................................................................................................................................16
            Mechanism of Action...................................................................................................................................................................................16
            R&D Progress .............................................................................................................................................................................................16
      CA-9 .................................................................................................................................................................................................................17
            Product Description ....................................................................................................................................................................................17
            Mechanism of Action...................................................................................................................................................................................17
            R&D Progress .............................................................................................................................................................................................17
      Carcinoembryonic Antigen ................................................................................................................................................................................18
            Product Description ....................................................................................................................................................................................18
            Mechanism of Action...................................................................................................................................................................................18
            R&D Progress .............................................................................................................................................................................................18
      D-3263 HCl .......................................................................................................................................................................................................19
            Product Description ....................................................................................................................................................................................19
            Mechanism of Action...................................................................................................................................................................................19
            R&D Progress .............................................................................................................................................................................................19
      DN24-02 ...........................................................................................................................................................................................................20
            Product Description ....................................................................................................................................................................................20
            Mechanism of Action...................................................................................................................................................................................20
            R&D Progress .............................................................................................................................................................................................20
      Lapuleucel-T .....................................................................................................................................................................................................21
            Product Description ....................................................................................................................................................................................21
            Mechanism of Action...................................................................................................................................................................................21
            R&D Progress .............................................................................................................................................................................................21
      Telomerase .......................................................................................................................................................................................................22
            Product Description ....................................................................................................................................................................................22
            Mechanism of Action...................................................................................................................................................................................22




Dendreon Corporation – Product Pipeline Review – H2 2011                                                                                                    GMDHC01747CDB / Published NOV 2011

©Global Markets Direct.. This report is a licensed product and is not to be photocopied                                                                                                                                 Page(2)
Dendreon Corporation – Product Pipeline Review



           R&D Progress .............................................................................................................................................................................................22
Dendreon Corporation – Pipeline Analysis...............................................................................................................................................................23
     Dendreon Corporation – Pipeline Products by Therapeutic Class......................................................................................................................23
     Dendreon Corporation - Pipeline Products By Target ........................................................................................................................................24
     Dendreon Corporation – Pipeline Products by Route of Administration .............................................................................................................25
     Dendreon Corporation – Pipeline Products by Molecule Type ...........................................................................................................................26
Dendreon Corporation – Recent Pipeline Updates..................................................................................................................................................27
Dendreon Corporation - Dormant Projects ...............................................................................................................................................................28
Dendreon Corporation - Discontinued Pipeline Products .........................................................................................................................................29
     Discontinued Pipeline Product Profiles ..............................................................................................................................................................29
           UK-279276 .................................................................................................................................................................................................29
Dendreon Corporation – Company Statement .........................................................................................................................................................30
Dendreon Corporation – Locations And Subsidiaries ...............................................................................................................................................32
     Head Office .......................................................................................................................................................................................................32
     Other Locations & Subsidiaries .........................................................................................................................................................................32
Dendreon Corporation - Key Manufacturing Facilities ..............................................................................................................................................33
Recent Developments .............................................................................................................................................................................................34
           Jun 30, 2011: Dendreon Announces Increased Capacity And Significant Reimbursement Decisions Supporting Broad Availability Of
           PROVENGE ...............................................................................................................................................................................................34
           Mar 30, 2011: Dendreon Issues Statement On CMS’s Proposed Decision Memo For PROVENGE ............................................................34
           Jun 29, 2011: FDA Approves Dendreon's Cancer Immunotherapy Manufacturing Facility At Los Angeles ..................................................35
           Mar 29, 2004: Dendreon's APC8024 immunotherapy Shows Long-Term Disease Stabilization And Significant Immune Response In
           Advanced, Metastatic Breast Cancer Patients ............................................................................................................................................35
           Jul 28, 2010: Dendreon Announces Publication Of Phase III PROVENGE IMPACT Study In New England Journal Of Medicine ...............36
           Apr 28, 2009: Data Presents Pivotal Phase III Study Data On PROVENGE For Treatment Of Advanced Prostate Cancer At AUA Annual
           Meeting.......................................................................................................................................................................................................37
           Apr 28, 2008: Dendreon Presents Preclinical Data Demonstrating Activity Of D-3263 In Benign Prostatic Hyperplasia At AUA 2009 Meeting
           ...................................................................................................................................................................................................................38
           Aug 26, 2011: Dendreon Receives FDA Approval For Atlanta Cancer Immunotherapy Manufacturing Facility ............................................39
           Oct 23, 2001: Dendreon Corporation Announces Taking License Rights from Geron Corporation For Telomerase Antigen ...................39
           Sep 21, 2005: Dendreon Announces Modulation Of Trp-p8 Significantly Inhibits Tumor Growth In Vivo .....................................................40
           May 21, 2008: Dendreon Initiates Phase 1 Clinical Trial Of Small Molecule Targeting TRPM8 In Cancer ...................................................40
           May 21, 2008: Dendreon Presents Preclinical Data Demonstrating Activity Of Trp-p8 agonist, D-3263, In Benign Prostatic Hyperplasia ....41
           Apr 19, 2009: Dendreon Reports Data On PROVENGE Potency And Long-Term Immune Responses In Androgen-Dependent Prostate
           Cancer ........................................................................................................................................................................................................42
           May 18, 2011: Dendreon Announces Clinical Trial Plans For DN24-02 At ASCO Annual Meeting ..............................................................43
           May 18, 2011: Dendreon Announces Clinical Trial Plans For PROVENGE At ASCO Annual Meeting ........................................................43
           May 18, 2011: Dendreon Announces Presentation Of PROVENGE Data At 2011 ASCO Annual Meeting ..................................................44
           Apr 18, 2005: Trp-p8 Agonists Significantly Inhibit Growth Of Trp-p8 Expressing Tumors In Vivo ...............................................................45
           Nov 17, 2010: Dendreon Reports MEDCAC Panel Reviewed PROVENGE Evidence .................................................................................45
           Oct 17, 2011: Dendreon Begins Enrollment In Phase II Neu-ACT Trial For Second Active Cellular Immunotherapy Product Candidate,
           DN24-02 .....................................................................................................................................................................................................46
           Aug 17, 2007: Dendreon Announces Publication Of Phase I Study Highlighting Immunologic And Clinical Activity Of Lapuleucel-T
           (Neuvenge) In Advanced Breast Cancer Patients .......................................................................................................................................47
           May 15, 2006: Dendreon Presents Data at American Association of Immunology Conference Highlights Potential New Active
           Immunotherapy for Treatment of Renal Cell Cancer ...................................................................................................................................48
           Nov 14, 2001: Corvas Announces Completion Of Recruitment In U.K.-279,276 (formerly rNIF) Trial; Next Steps, Follow Up and Data
           Analysis ......................................................................................................................................................................................................48
           Aug 13, 2002: Dendreon Corporation And Genentech To Collaborate On Trp-p8 Gene Platform ................................................................49
           Dec 11, 2004: Dendreon's APC8024 Immunotherapy Shows Promise In Advanced Breast Cancer ............................................................49
           Nov 11, 2010: Dendreon Submits Post-Approval Supplement To PROVENGE BLA For New Jersey Manufacturing Facility ......................50




Dendreon Corporation – Product Pipeline Review – H2 2
								
To top